In vivo

#Clinical trials #Drug toxicity #In vivo #Mouse models #Preclinical development

The in vivo tool enabling a confident transition to Phase I trials

This paper discusses the challenges drug developers face when transitioning from preclinical discovery to clinical trials and proposes expanding the drug development toolbox with humanised mouse models. Download the latest whitepaper to learn more about: The importance of selecting appropriate starting doses in clinical trials. Why humanised mice better predict… Read More

#Resources

#Artificial intelligence (AI) #In vivo #Mouse models #Oncology #Oxford Drug Design

In vivo testing validates new approach to cancer treatment

In vivo testing has validated Oxford Drug Design’s potential first-in-class approach against multiple tumours, designed using its AI platform. The results of a 28-day mouse trial showed clear efficacy as well as dose response. The company’s approach is based on a novel target, leucyl-tRNA… Read More

#Cancer Research #News

RNA
#Circio Holding #circular RNAs #Gene therapy #Genetic diseases #In vivo #mRNA

How does circVec technology compare to conventional mRNA? 

Circio has announced updated in vivo data that demonstrates a substantial durability advantage of Circio’s circVec technology over conventional mRNA expression. In addition, Circio has undertaken sequence optimisation resulting in a new circVec 2.2 design.   “The circVec 2.1 design is performing very well in… Read More

#News

Researcher in a medical lab
#Anti-inflammatory #Assay development optimisation & technology #Human disease models #In vitro #In vivo

From in vitro to in vivo: Effective translation for anti-inflammatory treatments

John Unitt, Vice President, Immunology and Inflammation Drug Discovery, at Sygnature Discovery, explores the importance of an effective translational process for preclinical and clinical success. The global anti-inflammatory therapeutics market was estimated to be $98.26 billion in 2022 and is forecast to reach $146.14 billion by 2032, growing at a… Read More

#Exclusive Content

RNA strand
#Circio Holding #circular RNAs #Gene therapy #Genetic diseases #In vivo #mRNA

Data demonstrates superiority of circular RNA vs linear mRNA

In vivo proof-of-concept for Circio Holding’s differentiated circVec platform approach to gene therapy has been demonstrated in two posters at the American Society of Gene & Cell Therapy (ASGCT) 2024 annual meeting. The in vivo data showed statistically significant higher expression level and durability for circVec… Read More

#News

Cell and gene therapy
#FDA #Gene editing #Gene therapy #iECURE #In vivo #Paediatrics

FDA approves first in vivo gene insertion programme in infants

iECURE has been given the go-ahead to begin US trials of its investigational gene editing-based therapy in newborn males with neonatal onset Ornithine Transcarbamylase (OTC) deficiency. The Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for ECUR-506 makes it the first in vivo gene… Read More

#Editor's Choice #News

#CAR-T #Cell and gene therapy #Cell therapy #Financing #In vivo #Investment

$175M financing will support development of in vivo CAR-T therapies

Biotechnology company Capstan Therapeutics has raised $175 million in an oversubscribed Series B financing. The proceeds will be used to advance CPTX2309, Capstan’s lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders, and to further develop Capstan’s tLNP pipeline. CPTX2309 delivers an… Read More

#Business & Investment #News

#Asgard Therapeutics #Cell and gene therapy #Financing #Immuno-oncology #In vivo

€30m raised for first-in-class in vivo cell reprogramming platform

Biotech Asgard Therapeutics has closed a €30 million Series A financing to support the development of its lead programme, AT-108. The company plans to submit an Investigational New Drug (IND) application to the FDA for AT-108 by 2026, expand and reinforce its research and development team, and fuel new reprogramming… Read More

#Business & Investment #News

#Astellas Pharma #CAR-T #Cell therapy #Collaboration #Immuno-oncology #In vivo #Kelonia Therapeutics #Xyphos Biosciences

Companies agree $800m deal for in vivo CAR-T cell therapy

Astellas-owned Xyphos Biosciences and Kelonia Therapeutics have entered into a research collaboration and license agreement to develop novel immuno-oncology therapeutics. Under the terms of the agreement, the companies plan to combine Kelonia’s iGPS with Xyphos’ ACCEL technology to develop in vivo CAR-T cell therapies targeting up to two programmes. Kevin… Read More

#Business & Investment #News #Trending News

T cell attacking cancer cell
#AbbVie #CAR-T #Collaboration #Haematology #In vivo #Umoja Biopharma

Collaboration boosts development of novel in-situ CAR-T cell therapies

AbbVie and Umoja Biopharma have entered into two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology. The first agreement provides AbbVie an exclusive option to license Umoja's CD19 directed in-situ generated CAR-T cell therapy candidates. This includes UB-VV111, Umoja's lead clinical programme… Read More

#Business & Investment #News

Gene therapy
#Cardiovascular disease #Gene editing #Genetics / genomics #In vivo #Verve Therapeutics

Single-course in vivo base editing therapy proven to lower cholesterol

A Phase Ib trial has shown low-density lipoprotein cholesterol (LDL-C) reductions up to 55% and blood PCSK9 protein reductions up to 84% after a single infusion of Verve Therapeutics’ Verve-101. The trial participants have heterozygous familial hypercholesterolemia (HeFH), a life-threatening inherited disease characterised by lifelong elevations… Read More

#News #Trending News

AI brain partnership
#ACROBiosystems #Diagnostics #Electrophysiology #In vivo #Neuroscience #Partnership

Partnership to accelerate neuroscience drug discovery  

ACROBiosystems, through ACRO Certify and under its Aneuro brand, has launched in vivo electrophysiology solutions for neuroscience research with Diagnostic Biochips.   Together, the two companies are committed to a collaborative effort to accelerate neurological drug discovery and commercialisation.  Electrophysiology is a critical part… Read More

#News

#Agilent #Biosafety testing #Drug discovery #In vivo #Infographic #Mitochondria

Learn new ways to identify mitochondrial liability

Download this new mitochondrial toxicity infographic by Agilent and discover the benefits of novel in vitro strategies for consumer safety. Drug-induced mitochondrial dysfunction has been linked to compound attrition, organ toxicity, black-box warnings, and market withdrawals. The infographic will help you: Gain an historical perspective on mitochondrial… Read More

#News

#Agilent #Biosafety testing #Drug discovery #In vivo #Infographic #Mitochondria

Learn new ways to identify mitochondrial liability

Download our mitochondrial toxicity infographic and discover the benefits of novel in vitro strategies for consumer safety. Drug-induced mitochondrial dysfunction has been linked to compound attrition, organ toxicity, black-box warnings, and market withdrawals. Our infographic will help you: Gain an historical perspective on mitochondrial toxicity. Understand the importance of testing… Read More

#Intelligence #Resources

Neurons
#App note #Cell culture #Human disease models #In vivo #Live cell analysis #Sartorius

App Note: Kinetically quantify neuronal outgrowth

Monitoring neuronal morphology in long-term in vitro cell cultures is critical for characterisation and evaluation of disease models and to understand neuronal development. Ideally, approaches to track neurite dynamics would allow continuous automated measurements of structural parameters, including neurite length and number of branch points. These methods should be non-perturbing… Read More

#News

#App note #Cell culture #Human disease models #In vivo #Live cell analysis #Sartorius

Kinetically quantify neuronal outgrowth using live-cell analysis

Monitoring neuronal morphology in long-term in vitro cell cultures is critical for characterisation and evaluation of disease models and to understand neuronal development. Ideally, approaches to track neurite dynamics would allow continuous automated measurements of structural parameters, including neurite length and number of branch points. These methods should be non-perturbing… Read More

#App Notes #Intelligence #Resources